Scientific Data Imperative: Establishing a New Benchmark After Two Decades

A groundbreaking research survey of 500 biopharma executives reveals why life sciences companies need to rethink their data platforms. Replatforming scientific data to an open cloud platform while transforming the data to FAIR (Findable, Accessible, Interoperable, Reusable) principles impacts three key industry drivers:

  • Speed: Learning from experiments faster, reducing time to market for final molecules
  • Cost: Improving productivity, increasing operational efficiency, increasing return on investment (ROI)
  • Risk: Improving safety, reducing errors, improving compliance with regulatory requirements

Executives say that replatforming scientific data to an open cloud platform would accelerate time to market by 65%.

Each one-day delay in getting a drug or therapeutic to market costs biopharmas an average of $1.26 million in lost revenue and/or loss of first-mover advantage.

Slowness to market and lost revenue are not the end of the story. Cloud ‘laggards’ spend 3.7X more on inefficient infrastructure compared to cloud leaders.

Download this report to calibrate your scientific data strategy.   Learn how utilizing FAIR data in the cloud is a game changer.

TetraScience International TA 110723

Your privacy is a top concern for us at Knowledge Hub Media. We’ll only use your personal information to provide you with the content, products and/or services you’ve requested from us. By clicking the "Submit" button below, you are confirming that you have carefully read Knowledge Hub Media’s Terms of Use agreement, and Privacy Policy, and agree to be legally bound by all such terms.